-
Updated Analysis Show Seagen's Tukysa Extended Median OS to Two Years with Benefits Maintained in Breast Cancer
Thursday, June 3, 2021 - 8:27am | 248Read More...Seagen Inc (NASDAQ: SGEN) has announced that improvements in overall survival (OS) and progression-free survival (PFS) were maintained with long-term follow-up from the HER2CLIMB trial of Tukysa (tucatinib) in metastatic breast cancer (MBC). The trial evaluated the addition of...
-
BriaCell Stock Doubles After Reporting Overall Survival Benefit in Pretreated Breast Cancer Patients
Wednesday, June 2, 2021 - 9:15am | 220Read More...BriaCell Therapeutics Corp (NASDAQ: BCTX) has provided an update on the overall survival (OS) data on its previously disclosed heavily pretreated advanced breast cancer patients. These women were treated with BriaCell’s lead candidate, Bria-IMT, as monotherapy, and also in...
-
Sanofi's Amcenestrant Combo Therapy Shows ORR of 34% In Breast Cancer Patients
Thursday, May 20, 2021 - 2:01pm | 287Read More...Sanofi SA (NASDAQ: SNY) revealed a new early peek at data from breast cancer candidate amcenestrant, an oral selective estrogen receptor degrader. Data will be presented at the 2021 American Society of Clinical Oncology Annual Meeting. In pooled data from the phase 1 AMEERA-1 trial...
-
Publication In Breast Cancer Research Indicate Brooklyn ImmunoTherapeutics' IRX-2 May Hold Promise In Early-Stage Breast Cancer
Tuesday, May 11, 2021 - 12:56pm | 332Read More...Brooklyn ImmunoTherapeutics Inc (NYSE: BTX) has announced a publication in Breast Cancer Research, which demonstrates how multiplex immunofluorescence (mIF) may be used to characterize the immunological activity of IRX-2 in early-stage breast cancer. IRX-2 is an allogeneic,...
-
AstraZeneca, Daiichi Sankyo Partnered ADC Shows Promise In Hard-To-Treat Breast Cancer
Monday, May 10, 2021 - 6:48am | 296Read More...AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OCTMKTS: DSNKY) have announced an update from their second antibody-drug conjugate (ADC) program that is showing promise in hard-to-treat breast cancer. The ADC, datopotamab deruxtecan, posted a 43% response rate and...
-
Veru's Stock Jumps As Enobosarm Shows Clinical Benefit In Heavily Pretreated Breast Cancer Patients
Wednesday, May 5, 2021 - 9:14am | 279Read More...Veru Inc (NASDAQ: VERU) has announced that the Phase 2 results evaluating enobosarm for breast cancer include further efficacy data and an analysis of patients who have failed estrogen blocking agents and CDK 4/6 inhibitors. Data will be presented at the European Society for...
-
Oncolytics Biotech's Pelareorep Associated With Therapeutic Efficacy, Improved Clinical Outcomes In Breast Cancer
Monday, April 12, 2021 - 10:23am | 379Read More...Oncolytics Biotech Inc (NASDAQ: ONCY), together with SOLTI, has announced new clinical data from the AWARE-1 window-of-opportunity breast cancer study evaluating pelareorep plus checkpoint blockade therapy. These data were presented at the American Association...
-
Greenwich LifeSciences' Stock Is Trading Higher After Breast Cancer Immunotherapy Shows 0% Recurrences Over 5 Years Follow-up
Friday, April 9, 2021 - 6:56am | 241Read More...Greenwich LifeSciences Inc (NASDAQ: GLSI) has announced the abstract results of the final 5-year immune response data of the Phase 2b trial at the 2021 AACR Annual Meeting. The company plans to publish the poster, the abstract, and an audio recording tomorrow in a joint...
-
Celcuity Stock Moves Higher After Licensing Pact With Pfizer For Gedatolisib In Breast Cancer
Friday, April 9, 2021 - 6:37am | 424Read More...Celcuity Inc (NASDAQ: CELC) has entered into a global licensing agreement with Pfizer Inc (NYSE: PFE), granting Celcuity exclusive rights to Pfizer's gedatolisib. The pan-PI3K/mTOR inhibitor is currently in Phase 1b trial to treat patients with ER+/HER2-...
-
Gilead's Trodelvy Wins FDA Regular Approval For Triple-Negative Breast Cancer
Thursday, April 8, 2021 - 6:47am | 355Read More...The FDA has granted regular approval to Gilead Sciences Inc's (NASDAQ: GILD) Trodelvy (sacituzumab govitecan) for an aggressive and tough-to-treat type of breast cancer. The indication covers people with unresectable locally advanced or metastatic triple-negative...
-
Monopar Therapeutics Is Trading Higher On Announcing Its uPA Radiotracer Along With Pet Imaging Can Detect Breast Cancer
Tuesday, March 30, 2021 - 10:13am | 197Read More...Monopar Therapeutics Inc (NASDAQ: MNPR) has announced the publication of a peer-reviewed study that demonstrated Monopar's Urokinase plasminogen activator (uPA) antibody fragment radiotracer could potentially identify breast cancers with uPA overexpression and monitor uPA...
-
FDA Rejects Merck's Keytruda Application In High-Risk Breast Cancer Patients
Tuesday, March 30, 2021 - 6:43am | 282Read More...The FDA slapped Merck & Co Inc’s (NYSE: MRK) Keytruda with a complete response letter in high-risk triple-negative breast cancer, in combination with chemotherapy as neoadjuvant treatment, then continuing as a single agent as adjuvant treatment after surgery....
-
Celcuity Teams Up With MD Anderson, Novartis, Puma Biotech To Study New Drug Regimen In Breast Cancer
Wednesday, March 17, 2021 - 9:28am | 287Read More...Celcuity Inc (NASDAQ: CELC) has announced a clinical trial collaboration with the MD Anderson Cancer Center, Novartis AG (NYSE: NVS), and Puma Biotechnology Inc (NASDAQ: PUMA) to conduct a Phase 2 clinical trial. The open-label Phase 2 trial will...
-
Exclusive: Greenwich LifeSciences CEO Calls Stock's Meteoric Rise 'Very Emotional'
Thursday, March 11, 2021 - 4:36pm | 646Read More...Greenwich LifeSciences, Inc. (NASDAQ: GLSI) is a biopharmaceutical company that is developing GP2, an immunotherapy to prevent breast cancer recurrences in certain patients. The stock skyrocketed nearly 3,000% in a single day in December after a Phase 2b trial suggested the therapy...
-
Athenex Shares Are Trading Lower After FDA Rejected Oral Paclitaxel Plus Encequidar Application In Breast Cancer
Monday, March 1, 2021 - 8:28am | 222Read More...The FDA has issued a complete response letter (CRL) for Athenex Inc’s (NASDAQ: ATNX) marketing application seeking approval for oral paclitaxel plus encequidar to treat metastatic breast cancer. The CRL indicated concern about an increase in neutropenia-related...
